Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
暂无分享，去创建一个
M. Rezai | P. Fasching | R. Kreienberg | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | G. von Minckwitz | J. Huober | C. Jackisch | C. Hanusch | H. Eidtmann | C. Solbach | B. Gerber | G. Minckwitz | P. Fasching | I. Schrader | M. Hauschild | H. Eggemann | C. Hanusch | K. Kittel | G. Kunz | B. Gerber